IBI112 clinical trials
Also written IBI112.
How each study uses IBI112 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IBI112 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Innovent Biologics (Suzhou) Co. Ltd. (5) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1)
Studies
Open first, then newest update. How each study uses IBI112 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingPhase 3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07265284Written as IBI112
- A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative ColitisCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT05377580Written as Period 2 IBI112 dose 3
- IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06049810Written as IBI112
- A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque PsoriasisCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT05645627Written as IBI112
- A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT05003531Written as IBI112 dose 2
- Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy SubjectsCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT04511624Written as IBI112 dose1